BLASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
5/8 — Partial
Priority Review
TEZSPIRE (tezepelumab-ekko) by AstraZeneca is thymic stromal lymphopoietin blockers [moa]. First approved in 2021.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEZSPIRE (tezepelumab-ekko) is a monoclonal antibody developed by AstraZeneca that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine in asthma inflammation. Approved in December 2021, it is indicated for the treatment of moderate-to-severe asthma in adult and adolescent patients. The drug represents a novel mechanism targeting a fundamental driver of type 2 inflammation, positioning it as a potential add-on therapy for patients inadequately controlled on existing biologics or conventional controllers.
$0.1BPart D
Mechanism of Action
Thymic Stromal Lymphopoietin Blockers
Pharmacologic Class:
Thymic Stromal Lymphopoietin Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
Started Nov 2026
210 enrolled
Severe Asthma
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
Started May 2026
230 enrolled
Chronic Rhinosinusitis With Nasal Polyps
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
Started Jan 2026
400 enrolled
Severe Asthma
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
Started Dec 2025
110 enrolled
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Asthma
Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma
Started Dec 2025
636 enrolled
Asthma
Worked on TEZSPIRE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.